Biomarin Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have BioMarin with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So with that, I'm going to turn it over to J.J. Bienaime, the CEO, to make some opening remarks, and then we'll jump into Q&A.
Thank you, Matthew, and we appreciate the opportunity to speak with you today. So starting with our most recent commercial product, VOXZOGO, for the treatment of children with achondroplasia. We were thrilled to announce 2 weeks ago that the European Commission granted approval for children ages
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
